NATCO Pharma Limited (NATCOPHARM) share price and analysis
NATCOPHARM last traded at ₹822.90 (-0.69%) on the NSE. Market cap ₹16,143 Cr (Small cap), Pharma & Healthcare sector.
Overall rating: 6.2/10 (Average)
- Valuation: 9.3/10
- Profitability: 10.0/10
- Growth: 0.0/10
- Financial health: 10.0/10
- Price trend: 1.7/10
Long-term view: Neutral (watchlist). A mixed picture. Wait for better value or a clearer trend. Trade bias (next few weeks): Strong short. Trend and momentum are clearly pointing down.
Strengths of NATCOPHARM
- Valuation (P/E) (P/E 17.9 vs sector 41.1): Trades about 56% below its sector's median P/E, so it's cheaper than peers. Make sure growth isn't the reason.
- Debt / equity (0.08): Virtually debt-free, with a strong balance sheet.
- Net profit margin (32.8%): Keeps ₹33 as profit from every ₹100 of revenue, a high-margin business.
- Analyst target (₹1,002 (+21.8%)): 9 analysts' average target implies +21.8%, strong upside.
- Momentum (RSI 14) (RSI 61): Strong bullish momentum without being overbought.
Weaknesses of NATCOPHARM
- Long-term trend (-11.1% vs 200-DMA): Well below its 200-day average, in a long-term downtrend.
- Revenue growth (YoY) (-44.7%): Sales are falling sharply.
- Profit growth (YoY) (-57.0%): Profits are falling sharply.
- 50-DMA vs 200-DMA (-12.7% gap): 50-day average is below the 200-day (death-cross setup), so medium-term momentum is down.
- 6-month performance vs Nifty 50 (-31.4% vs +7.4%): Badly underperforming the Nifty 50.
- 52-week range (33% below high): Near its 52-week low, under persistent selling pressure.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 17.9 | Cheaper than peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 17.5 | Profits expected flat | below today's P/E (17.9) and near 41 |
| Price / book | 1.60 | Low | 2–6 |
| EPS (TTM) | ₹45.89 | Profitable | above ₹0 |
| Return on equity | – | 15%+ (below 10% is weak) | |
| Debt / equity | 0.08 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 32.8% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 24.6% | Strong | 20%+ strong, below 10% thin |
| Revenue growth | -44.7% | Shrinking | 10%+ a year (below 3% is weak) |
| Profit growth | -57.0% | Falling | 10%+ a year (falling is weak) |
| Dividend yield | 0.73% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | – | 1.5+ (below 1 is tight) | |
| 52W high | ₹1,226.80 | 33% below · far from the high | price in the top 40% of its 52-week range |
| 52W low | ₹773.60 | Price is 6% above it | |
| 50-DMA | ₹808.16 | Price 1.8% above | price above it = short-term uptrend |
| 200-DMA | ₹926.00 | Price 11.1% below | price above it = long-term uptrend |
| 1Y return | +3.0% | In line with Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.18 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 47.6% | Moderate stake | 50%+ shows owner commitment |
| Institutions | 15.7% | Moderate interest | 30%+ is strong |
| Analyst target | ₹1,002.11 | 21.8% upside · 9 analysts | 8%+ upside |
Questions about NATCOPHARM
What is the share price of NATCO Pharma Limited (NATCOPHARM) today?
NATCOPHARM last traded at ₹822.90 (-0.69% on the day) on the NSE. Its 52-week range is ₹773.60 to ₹1,226.80. Prices are delayed and come from Yahoo Finance.
Is NATCOPHARM a good stock for the long term?
StockLens rates NATCOPHARM 6.2 out of 10 (Average) overall. Its long-term verdict is "Neutral (watchlist)": A mixed picture. Wait for better value or a clearer trend. Strengths: cheap vs peers, low debt, high margins. Concerns: downtrend, shrinking revenue, falling profits.
Is NATCOPHARM share overvalued?
NATCOPHARM trades at a P/E of 17.9 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 1.60.
Is NATCOPHARM good for short-term trading?
The trade bias for the next few weeks is "Strong short": Trend and momentum are clearly pointing down. The price is 11.1% below its 200-day average and 14-day RSI is 61.
Which stocks are similar to NATCOPHARM?
Similar Pharma & Healthcare stocks of comparable size include Granules India, Biocon, Alkem Laboratories, Glenmark Pharmaceuticals, Lupin. You can compare up to 4 of them side by side on StockLens.
About NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Stocks similar to NATCOPHARM
- Granules India share price
- Biocon share price
- Alkem Laboratories share price
- Glenmark Pharmaceuticals share price
- Lupin share price
- Max Healthcare share price
Compare NATCOPHARM with GRANULES, BIOCON, ALKEM
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.